The new channel, to be launched in the second quarter, is part of the company's plan to make genetic testing affordable and accessible to everyone.
Under the terms of the agreement, Yourgene will offer its NIPT products on Thermo's NGS instruments in Southeast Asia and pay off its debts to Thermo.
The company will compete by continuing product improvements, ramping up marketing presence, and launching an app to improve doctor and consumer engagement.
The firm plans to use the funding to drive sales of its preimplantation genetic screening tests and to invest in data science.
Illumina continues to forge partnerships with diagnostic developers overseas as it eyes approximately 50 population sequencing projects around the world.
The subsidiary is the Taiwan-based firm's first and potentially could provide it access to the genetic testing markets in Laos, Cambodia, Vietnam, and Indonesia.
Milu will help launch the test in countries including China as it works to develop a diagnostics business in Asia targeting maternal and women's health.
The company plans to focus on increasing its NIPT reimbursement as well as on pharmaceutical deals for its oncology test and launching a kidney transplantation test.
The firm's fourth quarter preliminary revenues increased by 11 percent to $865 million year over year, while full-year revenues jumped by 21 percent to $3.3 billion.
The infrared spectroscopy-based analyzer is designed to quantitatively measure the concentration of fat, carbohydrate, and protein in human milk.
Researchers tested the combined PGS and PGD assay in a pilot study and now aim to validate it on larger numbers of disorders and compare it to conventional testing.
The lab analytics service provides insurers with guidance aimed at helping them achieve improvements in quality performance metrics.
The company, which changed its name from Premaitha Health last month, saw a 73 percent increase in testing volumes during the first half of fiscal year 2018.
The company and Women & Infants Hospital of Rhode Island are currently evaluating the technology to determine the performance of the test.
Natera plans to launch its clinical oncology and transplantation tests next year and is hopeful that guidelines endorsing NIPT for average-risk pregnancies are imminent.
The platform, which Waters introduced last month, uses flow-injection tandem mass spectrometry to enable high-throughput analysis of dried blood spots.
Androvia LifeSciences has developed a predictive biomarker test that some clinicians are using to determine a man's fertility.
During the first year of the TRIDENT-2 study, 74,000 women opted for NIPT, which was switched from in-house-developed platforms to Illumina's VeriSeq in May of this year.
Asuragen's technology will be used in the Early Check study to identify children with rare health conditions, such as fragile X syndrome, before symptoms appear.
Regenerative therapeutics company StemCyte will offer Fulgent's Beacon Expanded Carrier Screening and Newborn Genetic Analysis testing services.